



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

2 00006

**Reagent:** vCB-41

**Catalog Number:** 3375

**Lot Number:**

**Provided:** 1 ml,  $10^{7.5}$  TCID<sub>50</sub>/ml

**Host or Recommended Host or Host Cells:** Virus stocks grown in HeLa S3 cells.

**Description:** Derived from WR parental vaccinia virus strain. Contains HIV-1 *env* gene from LAV isolate, excised from pNL4-3, (M. Martin, National Institutes of Allergy and Infectious Diseases, Bethesda, MD). *Env* gene cloned into plasmid pSC59 which contains a synthetic vaccinia strong early/late promoter (Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. *BioTechniques* **23**:1094-1097, 1997). Vaccinia recombinant generated by homologous recombination into the TK locus, and selection for TK- plaques using standard procedures.

**Special Characteristics:** Useful for expression of *env* glycoprotein for biochemical, immunologic, and functional studies.  
Sterility: Negative for bacteria, fungi, and mycoplasma.

**Recommended Storage:** -70degreeC.

**Contributor:** Dr. Christopher C. Broder, Paul E. Kennedy, and Dr. Edward A. Berger.

**References:** Broder CC, Berger EA. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. *Proc Natl Acad Sci USA* **92**: 9004-9008, 1995.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vCB-41 from Dr. Christopher C. Broder, Paul E. Kennedy, and Dr. Edward A. Berger." Also include the reference cited above in any publications.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: [hus@mail.nih.gov](mailto:hus@mail.nih.gov), Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.**

**Last Updated:**

June 24, 2013

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.